Clinical trial
A Phase 1, Double-blind, Placebo-Controlled, First-in-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses ofABBV-1162 in Healthy Subjects
NCT07832708 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Double-blind, Placebo-Controlled, First-in-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses ofABBV-1162 in Healthy Subjects
- Lead sponsor
- AbbVie
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- November 2, 2026
- Completion date
- May 31, 2027
- Enrollment
- 40 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
healthy volunteers